A New Era of Renal Denervation Trials for Patients With Hypertension?

The field of renal denervation for the treatment of hypertension has undergone a substantial set of dynamics during the past decade. Early unblinded and essentially uncontrolled trials reported stunning reductions in clinic blood pressure (BP) following renal denervation in patients with uncontrolled and/or treatment-resistant hypertension.1,2 However, the field fell apart when results of the first large, randomized, observer-blinded, and sham-controlled SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial3 did not show a BP-lowering effect of renal denervation compared to sham-operator treatment.

http://ift.tt/2DhFBTG